<?xml version="1.0" encoding="UTF-8"?>
<p>The WHO removed the designation of Zika a virus of global concern in 2018 as case rates have fallen. In March 2018, the WHO and the National Institutes of Allergy and Infectious Diseases (NIAID) convened a meeting of academics, representatives from industry, and regulators to discuss the approach to Zika virus vaccine development in an era of waning incidence [
 <xref rid="B7-tropicalmed-04-00104" ref-type="bibr">7</xref>]. Although Zika virus remains endemic in Asia, Africa, and Central and South America, current transmission rates, coupled with high background herd immunity, would require an extremely large and logistically difficult study. As population immunity wanes, future outbreaks are likely. The ability to conduct a meaningful future clinical trial may be dependent upon having pre-existing site and regulatory approvals with an established vaccine network to enable rapid response to new reports suggesting increased disease activity.
</p>
